The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).
 
Guillermo de Velasco
Employment - GlaxoSmithKline (I)
Consulting or Advisory Role - Pierre Fabre
 
Wanling Xie
No Relationships to Disclose
 
Frede Donskov
Research Funding - GlaxoSmithKline; Novartis; Pfizer
 
Laurence Albiges
Consulting or Advisory Role - Amgen; Novartis; Pfizer; Sanofi
Research Funding - Novartis (Inst); Pfizer (Inst)
 
Benoit Beuselinck
No Relationships to Disclose
 
Sandhya Srinivas
Consulting or Advisory Role - Genentech/Roche; medivation; pfizer
Research Funding - GlaxoSmithKline
 
Neeraj Agarwal
No Relationships to Disclose
 
Jae-Lyun Lee
Honoraria - Pfizer
Consulting or Advisory Role - Astellas Pharma
Research Funding - Pfizer
 
James Brugarolas
No Relationships to Disclose
 
Lori Wood
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Roche Canada (Inst)
Travel, Accommodations, Expenses - Novartis
Other Relationship - Janssen Oncology; Pfizer
 
Christian K. Kollmannsberger
No Relationships to Disclose
 
Sun Young Rha
No Relationships to Disclose
 
Scott A. North
Honoraria - Astellas Pharma; Janssen-Ortho; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Janssen Oncology; Novartis; Pfizer; Sanofi
 
Ravindran Kanesvaran
No Relationships to Disclose
 
Brian I. Rini
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Immatics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Reuben James Broom
No Relationships to Disclose
 
Haru Yamamoto
No Relationships to Disclose
 
Marina Dusevic Kaymakcalan
No Relationships to Disclose
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (Inst); GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)